Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources

Journal of Nuclear Medicine

Volumn 38, Issue 9, 1997, Pages 1374-1378

  Lim, Sang Moo ^b   DeNardo, Gerald L ^a   DeNardo, Diane A ^b   Shen, Sui ^b   Yuan, Aina ^b   O'Donnell, Robert T ^b   DeNardo, Sally J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Dosimetry; Iodine 131 Lym 1; Myelotoxicity; Radioimmunotherapy

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; MONOCLONAL ANTIBODY LYM 1 I 131; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CELL COUNT; BONE MARROW TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; HUMAN; IMAGE ANALYSIS; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY;

BLOOD; BLOOD CELL COUNT; BONE MARROW; HEMATOCRIT; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; REPRODUCIBILITY OF RESULTS;

EID: 0030885111     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. DeNardo DA, DeNardo GL, Yuan A, et al. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. J Nucl Med 1996;37:1970-1975.
2. Robertson JS, Godwin JT. Calculation of radioactive iodine BETA radiation dose to the bone marrow. Br J Radiol 1954;27:241-242.
3. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 1990;3:213-233.
4. 131I-Lym-1 in patients with B-cell malignancies. Nucl Med Commun 1993;14:587-595.
5. DeNardo SJ, Macey DJ, DeNardo GL. A direct approach for determining marrow radiation from MoAb therapy. In: Denardo GL, ed. Biology of radionuclide therapy. Washington, D.C.: American College of Nuclear Physicians, 1989:110-124.
6. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689-694.
7. Siegel JA, Lee RE, Pawlyk DA. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Nucl Med Biol 1989;16:553-559.
8. 131I-Lym-1 as a model. Cancer 1994;73:1038-1048.
9. Macey DJ, DeNardo SJ, DeNardo GL, DeNardo DA, Shen S. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. Clin Nucl Med 1995;20:117-125.
10. Siegel JA, Lee RE, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int J Rad Appl Instrum [B] 1989;16:553-559.
11. Buijs WC, Bassuger LF, Claessens RA, et al. Dosimetric evaluation of immunoscintigraphy using indium-111-labeled monoclonal antibody fragments in patients with ovarian cancer [Abstract]. J Nucl Med 1992;33(suppl): 1113P.
12. Juweid M, Sharkey RM, Siegel JA. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake. Cancer Res 1995;55(suppl):5827-5831.
13. Epstein AL, Zimmer AM, Spies SM, et al. Radioimmunodetection of human B-cell lymphomas with a radiolabeled tumor-specific monoclonal antibody (Lym-1). In: Cavalli F. Bonadonna G. Rozencweig GM, eds. Malignant lymphomas and Hodgkin's disease: experimental and therapeutic advances. Boston, MA: Martinus Nijhjoff, 1985:569-577.
14. Snyder WS, Ford MR, Warner GC. "S" absorbed dose per unit cumulated activity for selected radionuclides and organs. In: MIRD pamphlet 11. New York: Society for Nuclear Medicine, 1978.
15. Brodsky, A. CRC handbook of radiation measurements and protection, section A, volume II: biological and mathematical information. CRC Press, 1982:148-150.
16. Tubiana M, Frindel E, Croizat H, Parmentier C. Effects of radiations on bone marrow. Pathol Biol 1979;27:326-334.
17. 131I-labeled anti-CEA monoclonal antibodies. Cancer 1997:in press.
18. Morra E, Lazzareno M, Orlandi E, et al. Bone marrow and blood involvement by non-Hodgkin's lymphoma: clinicopathologic features and prognostic significance in relationship to the working formulation. In: Cavalli F, Bonadonna G, Rozencweig M, eds. Malignant lymphomas and Hodgkin's disease: experimental and therapeutic advances. Boston: Martinus Nijhoff Publishing; 1985:215-224.
19. Tardivon AA, Munck J-N, Shapeero LG, et al. Can clinical data help to screen patients with lymphoma for MR imaging of bone marrow? Ann Oncol 1995;6:795-800.
20. Stein R, Sharkey RM, Goldenberg DM. Hematological effects of radioimmunotherapy in cancer patients. Br J Haematol 1992;80:69-76.
21. Breitz HB, Durham JS, Fisher DR, Weiden PL. Radiation dose estimates to normal organs following intra-peritoneal Re-186-labeled monoclonal antibody: methods and results. Cancer Res 1995;55(23S):5817-5822.
22. Kassis AL. The MIRD approach: remembering the limitations. J Nucl Med 1992;33:781-782.